NEXLIZET and NEXLETOL are the only oral nonstatins FDA approved to lower bad cholesterol, and to reduce the risk of heart attack and heart procedures, like stent placement or bypass …

Discover NEXLIZET® and NEXLETOL®, approved to lower LDL-C and the risk of MI and coronary revascularization. See ISI and full prescribing information

Dec 2, 2024 · “Heart disease remains the number one cause of death globally, so we look forward to the opportunity to provide NEXLETOL and NEXLIZET as LDL cholesterol lowering and …

Dec 2, 2024 · “Heart disease remains the number one cause of death globally, so we look forward to the opportunity to provide NEXLETOL and NEXLIZET as LDL cholesterol lowering and …

In the cardiovascular outcomes trial [see Clinical Studies (14.2)], 16.4% of bempedoic acid-treated patients experienced clinically significant hyperuricemia reported as an adverse reaction...

NEXLIZET contains bempedoic acid and ezetimibe. NEXLIZET reduces elevated LDL-C through inhibition of cholesterol synthesis in the liver and absorption in the intestine.

May 8, 2025 · "Adding NEXLETOL and NEXLIZET to the HLS product portfolio is aligned with our stated BD strategy and will strengthen our position in the Canadian cardiovascular market."

Dec 2, 2024 · Esperion has submitted New Drug Submissions (NDSs) in Canada for Nexletol and Nexlizet, seeking approval for LDL-C reduction and cardiovascular risk management.

Dec 2, 2024 · Esperion has filed New Drug Submissions (NDSs) to Health Canada for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are …

Jun 16, 2025 · By adding Nexlizet to a treatment plan, patients may experience improved cardiovascular outcomes while minimizing side effects associated with other therapies. …